Ventyx Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-192.6	-192.96	-108.43	-85.3	-28.17	-4.33
Depreciation & Amortization	1.22	0.94	0.47	0.03	0	0
Share-Based Compensation	28.56	28.59	16.57	2.73	0.05	0.2
Other Operating Activities	-20.4	-3.09	-7.39	42.34	21.93	1.49
Operating Cash Flow	-183.23	-166.52	-98.77	-38.65	-6.2	-2.64
Capital Expenditures	-0.63	-0.51	-0.28	-0.26	0	0
Acquisitions	0	0	0	1.9	0	0
Change in Investments	162.23	101.45	-74.66	-216	0	0
Investing Cash Flow	161.6	100.94	-74.93	-214.37	0	0
Share Issuance / Repurchase	100.84	53.33	167.77	158.88	0	0
Debt Issued / Paid	0	0	0	0.45	6.13	2.95
Other Financing Activities	0.03	-	-	164.22	-	-
Financing Cash Flow	100.87	53.33	167.77	323.55	6.13	2.95
Exchange Rate Effect	-0.04	-0.01	-0.04	0.01	0	0
Net Cash Flow	79.2	-12.27	-5.97	70.55	-0.07	0.31
Free Cash Flow	-183.86	-167.04	-99.05	-38.91	-6.2	-2.64
Free Cash Flow Per Share	-2.97	-2.85	-1.89	-3.03	-3.12	-1.59

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).